Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale ...

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method that pulls apart the DNA molecule and amplifies the signal of | Roche said ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Caprock Group LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 3.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

The top opportunities in the genomic data analysis and interpretation market segmented by end-user will arise in the pharmaceutical and biotechnology companies segment, which will gain $756.71 million ...

Illumina, Inc offers sequencing- and array-based solutions for ... specific genes, and RNA or other genomic regions of interest.

With an installed base of more than 25,000 sequencing systems, Illumina holds around 80% of ... Avidity Biosciences (RNA 1.98%) develops targeted RNA therapeutics. It specializes in antibody ...

The manuscript addresses the 3D chromatin architecture in monocytes from patients with alcohol-associated hepatitis and its relationship to enhanced transcription of innate immune genes. While the ...